70 results about "Tuberculosis diagnosis" patented technology

The invention discloses a mycobacterium tuberculosis surface lipolysaccharide-antistatic nucleic acid aptamer and application thereof. The aptamer is a small molecular single-stranded deoxyribonucleic acid (ssDNA) which is specific to toxic mycobacterium tuberculosis surface lipolysaccharide ManLAM (Mannosylated Lipoarabinomannan) and has tuberculosis infection resisting and cellular immunity enhancing functions, and the nucleotide sequence of the ssDNA is shown as SEQIDNo.1. The small molecular ssDNA has a novel target spot and a novel structure which are different from those of the conventional anti-tuberculosis medicament, and has the immunologic suppression function of directly enclosing the ManLAM. The aptamer is easy to prepare and has low price; the obtained ssDNA aptamer is specifically combined on the surface of toxic mycobacterium tuberculosis; and the treatment targeting is further enhanced. The problems of increasing medicament tolerance and large side effect existing in the conventional treatment of tuberculosis are solved, and the aptamer can be taken as an effective novel anti-tuberculosis medicament or a tuberculosis diagnosis reagent.

The invention discloses preparation for Rv2645 protein, and the application thereof on aspects of tuberculosis diagnosis and recombination BCG vaccines. According to the preparation for Rv2645 protein and the application thereof, the Rv2645 protein in a tuberculosis gene RD10-14 zone is found to have the ability of inducing high-level gamma interferon, and when used for the diagnosis of the serum antibodies, especially IgG4 subtype antibodies, of a tuberculosis patient, has prominent statistics difference compared with the serum antibodies of healthy people; as the dominant antigen of the mycobacterium tuberculosis, the Rv2645 protein has the function of inducing high-level cellular immunity and humoral immunity, and can be used as a novel diagnostic reagent for tuberculosis; the Rv2645 protein can further be used for novel recombination BCG vaccines or protein vaccines for tuberculosis, the constructed recombination BCG capable of expressing the Rv2645 protein has the function of antituberculous immunity protection. According to the preparation for the Rv2645 protein and the application thereof provided by the invention, the Rv2645 protein is proved to have potential application value when used for tuberculosis diagnosis and reorganized BCG vaccines, so that the preparation and the application thereof has significant economic benefits.

Disclosed are methods and devices for analyzing aerosol particles in exhaled breath using diagnostic tools that enable rapid, low cost and autonomous point of care assays for several diseases including respiratory tract diseases. Disclosed are methods and devices for capturing exhaled breath aerosols in a packed bed column and analyzing exhaled captured breath aerosols for tuberculosis diagnosis.

The invention discloses a kit and primer pair combinations for distinguishing active tuberculosis patients and non-tuberculous pneumonia patients. The primer pair combinations include SEQ ID NO:1-2, SEQ ID NO:3-4 and SEQ ID NO:5-6, wherein the SEQ ID NO:1-2 corresponds to a CD157 gene, the SEQ ID NO:3-4 corresponds to an IL-1b gene, and the SEQ ID NO:5-6 corresponds to an MS4A6A gene. By adoptionof the primers for RT-PCR expansion and substitution of related gene expression level into an established formula, the active tuberculosis patients and the non-tuberculous pneumonia patients can be distinguished, and accuracy and quickness in tuberculosis diagnosis are realized.

The invention belongs to the field of biological medicines, and relates to an application of a molecular marker CLEC2B in tuberculosis diagnosis. The invention provides an application of a reagent fordetecting the expression level of the molecular marker CLEC2B in preparation of a kit for diagnosing tuberculosis.

The invention belongs to the biochemistry and immunology fields, relates to a protein and medicine composition used for tuberculosis diagnosis, and concretely relates to a separation protein. The amino acid sequence of the protein is shown in SEQ ID NO:1 or SEQ ID NO:2. The protein can be used as a molecular marker or a vaccine candidate for tuberculosis immunologic diagnosis in cellular level and has a good coincidence rate and reaction intensity.

The invention relates to application of five antigen proteins in identification and diagnosis of active tuberculosis, provides a diagnostic reagent, and particularly relates to a novel tuberculosis diagnosis method which comprises the following steps of by taking the five antigen proteins P22352, Q9P121, P15151, Q13291 and Q8NDA2 as biomarkers, detecting the content of the five antigen proteins in urine, and taking the quantity value of the specific content as a diagnostic index, and indicating a negative result in the normal value range. And if the concentration of any three or more antigen proteins exceeds or is lower than the normal value range, the result is judged to be positive.

The invention belongs to the technical field of medicine, and particularly relates to IgM (immunoglobulin M) specific protein Rv2915c of mycobacterium tuberculosis and an application of the IgM specific protein Rv2915c. The IgM specific protein Rv2915c and the application aim at providing a new choice for detecting tuberculosis. The protein Rv2915c adopts the technical scheme that an amino acid sequence of the protein Rv2915c of the mycobacterium tuberculosis is shown as SEQ ID No. 1 (sequence identifier number 1). The invention further provides the application of the protein Rv2915c of the mycobacterium tuberculosis in tuberculosis diagnosis. The invention further provides a diagnostic reagent for the tuberculosis. A main active ingredient of the diagnostic reagent is the protein Rv2915c of the mycobacterium tuberculosis. The invention further provides a diagnostic kit for the tuberculosis, which mainly comprises the protein Rv2915c of the mycobacterium tuberculosis. The IgM specific protein Rv2915c of the mycobacterium tuberculosis is applicable to the diagnosis of the tuberculosis.

The invention discloses tuberculosis proteins interacting with a human protein NRF1 and applications of the tuberculosis proteins. The invention provides an application of the human protein NRF1 in any one of the following processes of (A1) diagnosing tuberculosis; and (A2) preparing products for the diagnosing the tuberculosis. Screening and identification are carried out by using an MTB mycobacterium tuberculosis proteome chip-based protein-protein interaction experiment to obtain the tuberculosis proteins Rv2239c, Rv0577 and Rv2499c interacting with the human protein NRF1. The tuberculosisproteins can be used for diagnosing the tuberculosis or adjusting the activity of the human protein NRF1.

The invention belongs to the technical field of molecular biological technique, particularly relates to nucleotide mts 90 and the use of a fragment thereof in tuberculosis diagnosis and mainly aims at providing a novel selection for authentication of human mycobacterium tuberculosis and diagnosis of tuberculosis. The sequence of the nucleotide mts 90 is shown as SEQIDNO.1. A reagent for detecting the human mycobacterium tuberculosis is provided. The main component of the reagent is the nucleotide mts 90. A kit for detecting the human mycobacterium tuberculosis is provided and mainly comprises the nucleotide mts 90. The use of the mts 90 in the detection of the human mycobacterium tuberculosis is further provided. The nucleotide mts 90 can be used for authentication of the human mycobacterium tuberculosis and the diagnosis of the tuberculosis.

The invention discloses a gene-deleted recombinant bacillus calmette-guerin vaccine, and belongs to the technical field of zoonosis prevention and treatment. The gene deleted by the strain is a BCG_0349 gene with a nucleotide sequence shown as SEQ ID NO: 1. A homologous exchange substrate containing upstream and downstream homologous arms of the BCG_0349 gene is transduced into a bacillus calmette-guerin vaccine genome in a thermo-sensitive phage transducing mediated homologous recombination mode to knock out the BCG_0349 gene, the strain is successfully constructed, and it is confirmed for the first time that a deleted strain can promote expression and secretion of inflammatory cytokines of the organism and is weakened in toxicity; and specifically, the reduction of the forming ability ofthe soxhlet structure and the reduction of the phenotype and intracellular survival ability of small bacterial colonies are easier for removal of organisms, and the vaccine has good application potential in the related fields of tuberculosis diagnosis of human and animals, vaccine and drug development and the like.